Literature DB >> 11553687

The non-peptidyl fungal metabolite L-783,281 activates TRK neurotrophin receptors.

N Wilkie1, P B Wingrove, J G Bilsland, L Young, S J Harper, F Hefti, S Ellis, S J Pollack.   

Abstract

Neurotrophin binding to the extracellular surface of the Trk family of tyrosine kinase receptors leads to the activation of multiple signalling cascades, culminating in neuroregenerative effects, including neuronal survival and neurite outgrowth. Since neurotrophins themselves are not ideal drug candidates due to their poor pharmacokinetic behaviour and bioavailability, small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present study demonstrates that L-783,281, a non-peptidyl fungal metabolite, is capable of stimulating TrkA, B and C phosphorylation to various extents in CHO cells stably expressing human Trk receptors. L-783,281 also stimulated Trk phosphorylation in a number of rat and human primary neuronal cultures, whereas the highly similar compound, L-767,827, was without effect. Mechanistic studies utilizing transiently transfected PDGF/TrkA and TrkA/PDGF chimeras, demonstrated that L-783,281 is likely to interact with the intracellular domain of the TrkA receptor. Further investigations suggested that L-783,281 was nevertheless able to instigate receptor dimerization by binding in a non-covalent manner. Although the cytotoxicity of the compound was shown to preclude its effects in neuronal survival and neurite outgrowth assays, it is a prototype for a small molecule neurotrophin mimetic that activates Trk by interacting at a site different from the neurotrophin-binding site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553687     DOI: 10.1046/j.1471-4159.2001.00504.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Synthetic morphology: prospects for engineered, self-constructing anatomies.

Authors:  Jamie A Davies
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

2.  Alzheimer's disease drug development and the problem of the blood-brain barrier.

Authors:  William M Pardridge
Journal:  Alzheimers Dement       Date:  2009-09       Impact factor: 21.566

3.  Identification of a molecular activator for insulin receptor with potent anti-diabetic effects.

Authors:  Kunyan He; Chi-Bun Chan; Xia Liu; Yonghui Jia; Hongbo R Luo; Stefan A France; Yang Liu; W David Wilson; Keqiang Ye
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

4.  Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.

Authors:  Pei-Lun Hsu; Lin-Yea Horng; Kang-Yung Peng; Chia-Ling Wu; Hui-Ching Sung; Rong-Tsun Wu
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

5.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

6.  Identification of a small molecular insulin receptor agonist with potent antidiabetes activity.

Authors:  Guifen Qiang; Shenghui Xue; Jenny J Yang; Guanhua Du; Xiaobin Pang; Xiaoting Li; Devrishi Goswami; Patrick R Griffin; Eric A Ortlund; Chi Bun Chan; Keqiang Ye
Journal:  Diabetes       Date:  2014-04       Impact factor: 9.461

7.  Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library.

Authors:  Spyros Merkouris; Yves-Alain Barde; Kate E Binley; Nicholas D Allen; Alexey V Stepanov; Nicholas C Wu; Geramie Grande; Chih-Wei Lin; Meng Li; Xinsheng Nan; Pedro Chacon-Fernandez; Peter S DiStefano; Ronald M Lindsay; Richard A Lerner; Jia Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

8.  Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease.

Authors:  Shudan Wang; Hongyang Yao; Yihua Xu; Rui Hao; Wen Zhang; Hang Liu; Ying Huang; Wei Guo; Bai Lu
Journal:  Theranostics       Date:  2020-05-23       Impact factor: 11.556

9.  Activation of the insulin receptor by an insulin mimetic peptide.

Authors:  Junhee Park; Jie Li; John P Mayer; Kerri A Ball; Jiayi Wu; Catherine Hall; Domenico Accili; Michael H B Stowell; Xiao-Chen Bai; Eunhee Choi
Journal:  Nat Commun       Date:  2022-09-23       Impact factor: 17.694

10.  Non-peptidyl small molecule, adenosine, 5'-Se-methyl-5'-seleno-, 2',3'-diacetate, activates insulin receptor and attenuates hyperglycemia in type 2 diabetic Leprdb/db mice.

Authors:  Zi-Jian Lan; Zhenmin Lei; Alexandros Yiannikouris; Thirupathi Reddy Yerramreddy; Xian Li; Hayley Kincaid; Katie Eastridge; Hannah Gadberry; Chloe Power; Rijin Xiao; Lei Lei; Olivia Seale; Karl Dawson; Ronan Power
Journal:  Cell Mol Life Sci       Date:  2019-08-05       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.